Nuuron is a Berlin-based neurotechnology company developing a fully digital Alzheimer's therapy based on proprietary photonic neuromodulation. Founded in 2024 by Fabian Queisner and Dr. Markus Mueschenich, with Priv.-Doz. Dr. Julian Keil as Scientific Director, the company aims to activate the memory system of Alzheimer's patients through its "Memory Pacemaker" platform.

The technology produces ultra-high-frequency, digital-photonic stimuli delivered through VR and AR headsets that use the retina as an interface into the brain. The stimulation protocols are generated by proprietary algorithms designed to activate neural circuits involved in memory formation and recall. The approach is framed as a digital disease-modifying therapy, distinct from pharmacological interventions that target neurochemistry, and is designed to be prescribed by doctors and reimbursed by health insurers.

Nuuron is conducting preclinical animal studies in collaboration with the German Center for Neurodegenerative Diseases (DZNE) and preparing a clinical trial with Alzheimer's patients at Charite. The company has entered a strategic partnership with RoX Health, a subsidiary of Roche, and raised EUR 3.5 million in an oversubscribed seed round led by High-Tech Gruenderfonds. Market entry is planned for both Europe and the United States.